temozolomide
Selected indexed studies
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). (J Clin Oncol, 2023) [PMID:36260828]
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. (Lancet, 2019) [PMID:30782343]
- Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. (Biochim Biophys Acta Rev Cancer, 2021) [PMID:34419533]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). (2023) pubmed
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. (2019) pubmed
- Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. (2021) pubmed
- Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase. (2023) pubmed
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. (2012) pubmed
- Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery. (2024) pubmed
- Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma. (2025) pubmed
- Temozolomide for aggressive pituitary tumors:-A literature review. (2024) pubmed
- Temozolomide for immunomodulation in the treatment of glioblastoma. (2018) pubmed
- Evidence-Based Practice: Temozolomide Beyond Glioblastoma. (2019) pubmed